Fenofibrate inhibits angiogenesis in vitro and in vivo
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Fenofibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, used as a normolipidemic agent, is thought to offer additional beneficial effects in atherosclerosis. Since angiogenesis is involved in plaque progression, hemorrhage, and instability, the main causes of ischemic events, this study was designed to evaluate the action of fenofibrate on angiogenesis. Our results show that fenofibrate (i) inhibits endothelial cell proliferation induced by angiogenic factors, followed at high concentrations by an increase in apoptosis, (ii) inhibits endothelial cell migration in a healing wound model, (iii) inhibits capillary tube formation in vitro, and (iv) inhibits angiogenesis in vivo. Concerning the mechanism of action, the inhibition of endothelial cell migration by fenofibrate can be explained by a disorganization of the actin cytoskeleton. At the molecular level, fenofibrate markedly decreased basic fibroblast growth factor-induced Akt activation and cyclooxygenase 2 gene expression. This inhibition of angiogenesis could participate in the beneficial effect of fenofibrate in atherosclerosis.
- Fenofibrate inhibits angiogenesis in vitro and in vivo
Cellular and Molecular Life Sciences CMLS
Volume 60, Issue 4 , pp 810-819
- Cover Date
- Print ISSN
- Online ISSN
- Birkhäuser Verlag
- Additional Links
- Key words. Angiogenesis; atherosclerosis; fenofibrate; Akt; cyclooxygenase 2; peroxisome proliferator activated receptor.
- Industry Sectors
- Author Affiliations
- A1. Laboratoire DIFEMA, Faculté de Médecine et Pharmacie, 22 Boulevard Gambetta, 76183 Rouen (France), Fax +33 2 35 14 83 40, e-mail: email@example.com, FR
- A3. Institut Gustave Roussy, 95 Villejuif (France), FR
- A4. Centre National de Recherche Scientifique (CNRS), IFR 2249, Villejuif (France), FR
- A2. Laboratoire de Biochimie et Equipe Mixte Institut National de la Santé et de la Recherche Médicale (INSERM) 99-12, Hôtel-Dieu, 75 Paris (France), FR